References
- Chen W, Zheng R, Zhang S, et al (2013). Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res, 25, 10-21.
- Contu SS, Contu PC, Damin DC, et al (2007). pRB expression in esophageal mucosa of individuals at high risk for squamous cell carcinoma of the esophagus. World J Gastroenterol, 13, 1728. https://doi.org/10.3748/wjg.v13.i11.1728
- De Laurentiis M, Cancello G, D'Agostino D, et al (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clinical Oncol, 26, 44-53. https://doi.org/10.1200/JCO.2007.11.3787
- Dey B, Raphael V, Khonglah Y, et al (2014). Immunohistochemical Analysis of P53 and PRB in Esophageal Squamous Cell Carcinoma. J Clin Diagn Res, 8, 1-3. https://doi.org/10.1111/crj.12028
- Fabi A, Barduagni M, Ferraresi V, et al (2004). The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res, 23, 25-32.
- Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
- Giacinti C, Giordano A (2006). RB and cell cycle progression. Oncogene, 25, 5220-7. https://doi.org/10.1038/sj.onc.1209615
- Hirabayashi M, Endoh K, Teramachi M, et al (2004). Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer, 44, 355-62. https://doi.org/10.1016/j.lungcan.2003.12.001
- Julian LM, Palander O, Seifried LA, et al (2008). Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene, 27, 1572-9. https://doi.org/10.1038/sj.onc.1210803
- Kurtyka CA, Chen L, Cress WD (2014). E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One, 9, 96357. https://doi.org/10.1371/journal.pone.0096357
- Lee L-F, Li G, Templeton DJ, et al (1998). Paclitaxel (Taxol)- induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biological Chemistry, 273, 28253-60. https://doi.org/10.1074/jbc.273.43.28253
- Manfredi JJ, Parness J, Horwitz SB (1982). Taxol binds to cellular microtubules. J Cell Biol, 94, 688-96. https://doi.org/10.1083/jcb.94.3.688
- Martinez-Cruz AB, Santos M, Lara MF, et al (2008). Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res, 68, 683-92. https://doi.org/10.1158/0008-5472.CAN-07-3049
- Milross CG, Mason KA, Hunter NR, et al (1996). Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst, 88, 1308-14. https://doi.org/10.1093/jnci/88.18.1308
- Ozkaya S, Findik S, Dirican A, et al (2012). Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med, 4, 1035-8.
- Rigas JR (2004). Taxane-platinum combinations in advanced non-small cell lung cancer: A review. Oncologist, 9, 16-23.
- Rozzi A, Nardoni C, Corona M, et al (2010). Weekly Regimen of Paclitaxel and Carboplatin as First-Line Chemotherapy in Elderly Patients with Stage IIIB-IV Non Small Cell Lung Cancer (NSCLC): Results of a Phase II Study. J Chemotherapy, 22, 419-23. https://doi.org/10.1179/joc.2010.22.6.419
- Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7. https://doi.org/10.1038/277665a0
- Suyama H, Igishi T, Sano H, et al (2004). ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. Int J Oncol, 24, 1499-504.
- van den Broek GB, Wildeman M, Rasch CR, et al (2009). Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatinbased chemoradiation. Int J Cancer, 124, 2643-50. https://doi.org/10.1002/ijc.24254
- Wang MT, Zhang JJ, Xu LY, et al (2013). Invasive and prognostic significance of pRB in esophageal squamous cell carcinoma: a meta-analysis. Dis Esophagus, 26, 723-8.
- Wang TH, Wang HS, Soong YK (2000). Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer, 88, 2619-28. https://doi.org/10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J
- Yamamoto Y, Shimizu E, Masuda N, et al (1998). RB protein status and chemosensitivity in non-small cell lung cancers. Oncol Rep, 5, 447-51.
- Zhao J, Zhang Z, Liao Y, et al (2014). Mutation of the retinoblastoma tumor suppressor gene sensitizes cancers to mitotic inhibitor induced cell death. Am J Cancer Res, 4, 42-52.